Trials Today

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Purpose

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.

Condition

Psoriasis

Eligibility

Eligible Ages: Over 18 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Participants must have been diagnosed with psoriasis for at least 6 months - Participants must have active psoriasis plaques - Participants must be willing and able to have skin biopsies (small samples of skin removed for testing)

Exclusion Criteria

Participants must not have received certain medications for psoriasis that are applied to the skin within 14 days prior to baseline (Day 1) - Participants must not have received certain oral or injectable medications or light therapy for psoriasis within 4 weeks prior to baseline

Study Design

Phase: Phase 1
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Basic Science
Masking: Double (Participant, Investigator)

Arm Groups

Arm	Description	Assigned Intervention
Experimental LY3462817 - Intravenous (IV)	LY3462817 administered as IV infusions.	Drug: LY3462817 - IV Administered IV
Placebo Comparator Placebo - IV	Placebo administered as IV infusions.	Drug: Placebo - IV Administered IV
Experimental LY3462817 - Subcutaneous (SC)	LY3462817 administered as SC injections. (SC administration is discretionary/optional.)	Drug: LY3462817 - SC Administered SC
Placebo Comparator Placebo - SC	Placebo administered as SC injections. (SC administration is discretionary/optional.)	Drug: Placebo - SC Administered SC
Experimental LY3509754	LY3509754 administered orally.	Drug: LY3509754 Administered orally.
Placebo Comparator Placebo	Placebo administered orally.	Drug: Placebo - IV Administered IV Drug: Placebo - SC Administered SC Drug: Placebo Administered orally.

Recruiting Locations

More Details

NCT ID: NCT04152382
Status: Terminated
Sponsor: Eli Lilly and Company

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.